These findings highlight that METTL3 enhances M2‐driven MMT in renal fibrosis during CAR by promoting the TGF‐β1/Smad3 axis, suggesting that METTL3 is a promising therapeutic target for mitigating renal fibrosis in CAR. Here, SMAD3 is linked to renal fibrosis.